CMV prophylaxis in high-risk renal transplant patients (D+/R-) by acyclovir with or without hyperimmune (CMV) immunoglobulins: A prospective study

American Journal of Nephrology

Volumn 17, Issue 6, 1997, Pages 489-494

  Rostaing, Lionel ^a   Martinet, Olivier ^a   Cisterne, Jean Marc ^a   Icart, Josette ^a   Chabannier, Marie Hélène ^a   Durand, Dominique ^a  

^a CHU RANGUEIL   (France)

Author keywords

Acyclovir; Anti cytomegalovirus; Cytomegalovirus; Immunoglobulins; Immunosuppression; Rejection; Renal transplantation

Indexed keywords

ACICLOVIR; CYTOMEGALOVIRUS ANTIBODY; HYPERIMMUNE GLOBULIN;

ARTICLE; CADAVER KIDNEY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIREMIA;

ACYCLOVIR; COMBINED MODALITY THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOGLOBULINS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0030670975     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000169175     Document Type: Article

References (26)

1. Ho M: Epidemiology of cytomegalovirus infection. Rev Infect Dis 1990:2:701-710.
2. Rubin RH: Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990:12:754-766.
3. Plotkin DA, Higgins R, Kurtz JB. et al: Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994:58:1176-1178.
4. Hirsh MS, Schoolev RT, Cosimi BA, et al: Effects of interferon alpha on cytomegalovirus reactivation syndromes in renal transplant recipients. N Engl J Med 1983:308:1490-1493.
5. Kovarik J, Mayer G, Pohanka E, et al: Adverse effect of low dose prophylactic human recombinant leucocyte interferon alpha treatment in renal transplant recipients. Transplantation 1988;45:402-405.
6. Balfour HH: Management of cytomegalovirus disease with antiviral drugs. Rev Infect Dis 1990:12:849-860.
7. Rondeau E. Bourgeons B. Pcraldi MN, et al: Prophylaxie des infections à cytomegalovirus par le ganciclovir chez les receveurs de greffe de rein. Presse Méd 1992;21:979-980.
8. Sleinmuller DR, Graneto D, Swift C. et al: Use of intravenous immunoglobulin prophylaxis of primary cytomegalovirus infection post living-related donor renal transplantation. Transplant Proc 1989;21:2069-2071.
9. Conti JD, Freed BM, Lempert N: Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease. Transplant Proc 1993;25:1421-1422.
10. Snvdam DR, Werner BG, Tilnev M. et al: Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immunoglobulin: Comparison of the randomized and open-label trials. Transplant Proc 1991;23:1357-1360.
11. Fassbinder W, Ernst W, Hankc P. et al: Cytomegalovirus infection after renal transplantation: Effect of prophylactic hvperimmunoglobulin. Transplant Proc 1986; 18:1393-1396.
12. Balfour HH, Chace BA, Stapleton JT. et al: A randomized placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989:320:1381-1387.
13. Vasquez EM, Sanchez J, Poliak R, el al: High-dose oral acyclovir prophylaxis for primary cytomegalovirus infection in seronegative renal allograft recipient. Transplantation 1992:55: 448-450.
14. Wong T, Toupance O, Chanard J: Acyclovir to prevent cytomegalovirus after renal transplantation. Ann Intern Med 1991:1 15:68.
15. Bailey TC, Neil A. et al: Failure of high-dosc oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993;95:273-278.
16. Legendre C, Ducloux A, Ferroni N, et al: Acyclovir in preventing cytomegalovirus infection in kidney transplant recipient: A case-controlled study. Transplant Proc 1993:25:1431-1433.
17. Nicol DL, McDonald AS, Belitsky P. et al: Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients. Transplantation 1993;55:841-846.
18. Plotkin SA, Starr S, Freidman HM. et al: Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med 1991;114:525-531.
19. Flesher CV, Englund JA, Edelman CK, et al: Pharmacologic basis of high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrobial Agents Che-mother 1991:5:938-943.
20. Simmons RL, Weil R, Tallent MB, et al: Do mild infections trigger the rejections of renal allograft? Transplant Proc 1970:2:419-433.
21. Poutcil-Noble C, Ecochard R, Landivron G. et al: Cytomegalovirus infection. An etiological factor for rejection. Transplantation 1993:55: 851-857.
22. Ranjan D, Burke G, Esquenazi V. et al: Factors affecting the ten-years outcome of human renal allografts. Transplantation 1991:51:113-117.
23. Petersen P, Schnceberger H, Schleibner S, et al: Positive donor negative recipient cytomegalovirus status is a detrimentral factor for longterm renal allograft survival. Transplant Int 1994:7:336-338.
24. Beasles P, Almond MK, Kwan JTC: Acyclovir neurotoxicity: Prevention and therapy in patients on haemodialysis. Nephron 1994:66: 362-363.
25. McCarthy JM, Karim MA, Krueger H, et al: The cost impact of cytomegalovirus disease in renal transplant patients. Transplantation 1993:55:1277-1282.
26. Snydam DR: Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 1990; 12: 839-848.